Managing Cabozantinib-induced Dysgeusia: Mechanisms, Clinical Impact, and Strategies for Improved Oncology Outcomes
Oghenetanure Ryan Enaworu, Monsurat Nasiru, Urmila Palla, Enibokun Theresa Orobator, Moyosore Taiwo, Wuraola Awosan & Ozioma Esther Onuselogu · Journal of Cancer and Tumor International · 2025
Cabozantinib, a potent tyrosine kinase inhibitor (TKI), targets vascular endothelial growth factor receptor (VEGFR), mesenchymal-epithelial transition factor (MET), and AXL receptor tyrosine kinase to inhibit tumour angiogenesis, metastasis, and proliferation in advanced renal ce...
Open access
Research Article
10.9734/jcti/2025/v15i2292